Cumberland Pharmaceuticals Inc (CPIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has a cash flow conversion efficiency ratio of 0.010x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($172.83K) by net assets ($17.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CPIX market cap for the company's overall valuation and market capitalisation.
Cumberland Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Cumberland Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cumberland Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore CPIX operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
After You Public Company Limited
BK:AU
|
0.122x |
|
Prime Securities Limited
NSE:PRIMESECU
|
-0.056x |
|
Shree Digvijay Cement Co.Ltd
NSE:SHREDIGCEM
|
-0.145x |
|
Quartzsea Acquisition Corporati
NASDAQ:QSEA
|
-0.002x |
|
Golf & Co Group Ltd
TA:GOLF
|
0.136x |
|
Nahar Spinning Mills Limited
NSE:NAHARSPING
|
0.219x |
|
MICROPORT CARDIO.MEDTECH.
F:72X
|
N/A |
|
Supergas Energy Ltd
TA:SPGE
|
0.058x |
Annual Cash Flow Conversion Efficiency for Cumberland Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Cumberland Pharmaceuticals Inc from 2005 to 2025. View Cumberland Pharmaceuticals Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.54 Million | $4.93 Million | 0.201x | +840.13% |
| 2024-12-31 | $22.55 Million | $-612.19K | -0.027x | -113.04% |
| 2023-12-31 | $29.26 Million | $6.09 Million | 0.208x | -11.37% |
| 2022-12-31 | $35.97 Million | $8.45 Million | 0.235x | +57.84% |
| 2021-12-31 | $42.60 Million | $6.34 Million | 0.149x | +28.87% |
| 2020-12-31 | $46.87 Million | $5.42 Million | 0.116x | +93.09% |
| 2019-12-31 | $51.09 Million | $3.06 Million | 0.060x | +6.81% |
| 2018-12-31 | $55.57 Million | $3.11 Million | 0.056x | +742.00% |
| 2017-12-31 | $63.92 Million | $-557.71K | -0.009x | -212.03% |
| 2016-12-31 | $73.12 Million | $569.48K | 0.008x | -89.82% |
| 2015-12-31 | $76.82 Million | $5.88 Million | 0.077x | -7.70% |
| 2014-12-31 | $80.75 Million | $6.69 Million | 0.083x | +780.86% |
| 2013-12-31 | $79.29 Million | $746.13K | 0.009x | -88.72% |
| 2012-12-31 | $85.57 Million | $7.14 Million | 0.083x | -20.81% |
| 2011-12-31 | $82.84 Million | $8.72 Million | 0.105x | +2260.53% |
| 2010-12-31 | $77.72 Million | $346.66K | 0.004x | -20.45% |
| 2009-12-31 | $72.22 Million | $404.97K | 0.006x | -98.46% |
| 2008-12-31 | $17.55 Million | $6.40 Million | 0.364x | -29.26% |
| 2007-12-31 | $16.75 Million | $8.63 Million | 0.515x | +164.95% |
| 2006-12-31 | $11.13 Million | $2.16 Million | 0.194x | -49.83% |
| 2005-12-31 | $6.23 Million | $2.42 Million | 0.388x | -- |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more